Tuesday 16 August 2022 - 03:01
In Business 42 Years - Since 1980
PLEASE NOTE: During August 2022 we are doing a comprehensive revision of our customer service workflow. This includes training of current and new personnel. We are expecting that these changes will have only very minimal effects on our overall order processing and shipping activities. However, we do ask any customers who prefer that their shipments go out on Fridays to contact our Customer Service group and let them know about your preferences in advance. Thank you.
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
P-5115 Pemafibrate, Free Acid, >99%
Synonyms : [K-877] [R-K-13675]
Related Terms : [Parmodia]
- Size
- US $
- €
- £
- ¥
- 1 mg
- 43
- 42
- 35
- 5,700
- In stock
- 5 mg
- 64
- 62
- 52
- 8,500
- In stock
- 10 mg
- 98
- 96
- 81
- 13,000
- In stock
- 25 mg
- 199
- 195
- 164
- 26,400
- In stock
- 50 mg
- 340
- 333
- 281
- 45,100
- In stock
- 100 mg
- 520
- 509
- 430
- 69,000
- In stock
- 200 mg
- 874
- 856
- 722
- 116,000
- In stock
- 500 mg
- 1,790
- 1,754
- 1,480
- 237,500
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 490.55
- C28H30N2O6
- [848259-27-8]
Solubility: DMSO.
- Pemafibrate, also known as K-877, is a selective peroxisome proliferator-activated receptor [alpha] (PPAR[alpha]) modulator and a next-generation PPAR[alpha] agonist. It activated PPAR[alpha], PPAR[gamma], and PPAR[delta] with EC50 values of 1 nM, 2.3 uM, and 1 uM, respectivey. Fruchart J.C. "Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists." Cardiovasc Diabetol. 12: 82 (2013).
- When compared to placebo and fenofibrate, pemafibrate improved triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and other lipid parameters without increasing adverse events or adverse drug reactions in dyslipidaemic patients with high TG and low HDL-C. Ishibashi S., et al. "Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial." Atherosclerosis 249: 36-43 (2016).
- Pemafibrate suppressed diet-induced obesity; decreased plasma glucose, insulin and TG levels; increased plasma fibroblast growth factor 21 in mice; and improved their obesity-related metabolic abnormalities. Araki M., et al. "The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice." Int. J. Mol. Sci. 19(7): 2148 (2018).
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
